The Technical Analyst
Kalvista Pharmaceuticals [KALV]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Kalvista Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
4.56% $13.76
Last updated: 7 aug 2022 - 23:52
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 338.10 mill |
| EPS: | -3.05 |
| P/E: | 0.000 |
| Earnings Date: | Sep 07, 2022 |
| SharesOutstanding: | 24.57 mill |
| Avg Daily Volume: | 0.317 mill |
| RATING 2022-08-05 |
|---|
| B |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$15.02 (9.13%) $1.256 |
| Date: 2022-08-08 |
| Expected Trading Range (DAY) |
|---|
|
$ 13.11 - 14.41 ( +/- 4.69%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-05-26 | Treanor Patrick | Buy | 17 000 | Stock Option (right to buy) |
| 2022-05-17 | Yea Christopher | Buy | 28 380 | Restricted Stock Units |
| 2022-05-17 | Yea Christopher | Buy | 18 920 | Employee Stock Option (Right to Buy) |
| 2022-05-17 | Feener Edward P. | Buy | 28 380 | Restricted Stock Units |
| 2022-05-17 | Feener Edward P. | Buy | 18 920 | Employee Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 50.60 |
| Last 100 transactions |
| Buy: 1 426 543 | Sell: 517 779 |
Forecast:
16:00 - $13.76
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $13.76
Forecast 2: 16:00 - $13.76
Forecast 3: 16:00 - $13.76
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $13.76 (4.56% ) |
| Volume | 0.153 mill |
| Avg. Vol. | 0.317 mill |
| % of Avg. Vol | 48.14 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KALV
112 Signals | Accuracy: 20.54% | Accuracy Buy: 21.43% | Accuracy Sell: 19.64%
Avg return buy: -0.04 % | Avg return sell: 0.01 %
$1 invested is now $0.98 or -2.37% since 25-07-22
| Date | Signal | @ | Closed | % | Aug 5 - 14:59 | buy | $13.13 | N/A | Active |
|---|---|---|---|---|
| Aug 5 - 14:28 | sell | $13.06 | $13.13 @ Aug 5 - 14:59 | 0.56% |
| Aug 5 - 14:15 | buy | $13.07 | $13.06 @ Aug 5 - 14:28 | -0.08% |
| Aug 5 - 14:07 | sell | $13.05 | $13.07 @ Aug 5 - 14:15 | 0.11% |
| Aug 5 - 14:02 | buy | $13.07 | $13.05 @ Aug 5 - 14:07 | -0.15% |
| Aug 5 - 12:48 | sell | $13.09 | $13.07 @ Aug 5 - 14:02 | -0.16% |
| Aug 5 - 12:45 | buy | $13.13 | $13.09 @ Aug 5 - 12:48 | -0.28% |
| Aug 5 - 12:44 | sell | $13.11 | $13.13 @ Aug 5 - 12:45 | 0.17% |
| Aug 5 - 12:19 | buy | $13.08 | $13.11 @ Aug 5 - 12:44 | 0.19% |
| Aug 4 - 15:02 | sell | $13.24 | $13.08 @ Aug 5 - 12:19 | -1.21% |
KALV
Latest Press Releases
2022-07-07 06:45:00 - Press Release
Kalvista Pharmaceuticals Provides Operational Update And Fiscal Year Financial Results
Cambridge, mass. & salisbury, england--(business wire)--kalvista pharmaceuticals, inc. (nasdaq: kalv), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal year ended april 30, 2022. “we are pleased with the progress we have made over the last fiscal year in the development of the candidates in our oral hereditary angioed
2022-07-05 06:45:00 - Press Release
Kalvista Pharmaceuticals Presents New Data For Sebetralstat And Its Oral Factor Xiia Inhibitor Program
Cambridge, mass. & salisbury, england--(business wire)---- $kalv--kalvista pharmaceuticals, inc. (nasdaq: kalv), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, has presented data for its oral on demand plasma kallikrein (pka) inhibitor and factor xiia (fxiia) programs at the eaaci2022 conference in prague, czech republic. kalvista presented data showing sebetralstat was an effective treatment for both perip
2022-06-03 07:00:00 - Press Release
Kalvista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cambridge, mass. & salisbury, england--(business wire)---- $kalv--kalvista pharmaceuticals, inc. (nasdaq: kalv), today announced that the compensation committee of kalvista's board of directors granted one newly-hired employee inducement options to purchase an aggregate of 20,000 shares of kalvista common stock on june 1, 2022 as inducement material to such employee entering into employment with kalvista. the options were granted in accordance with nasdaq listing rule 5635(c)(4). the options have an exer
2022-05-27 06:45:00 - Press Release
Kalvista Pharmaceuticals Announces Changes To Board Of Directors
Cambridge, mass. & salisbury, england--(business wire)---- $kalv--kalvista pharmaceuticals, inc. (nasdaq: kalv), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that patrick a. treanor has been appointed and dan soland is resigning from the company's board of directors. both changes are part of a planned transition and are effective immediately. mr. treanor is currently chief operating office
2022-05-17 06:45:00 - Press Release
Kalvista Pharmaceuticals Announces Non-proprietary Name Selection For Kvd900
Cambridge, mass. & salisbury, england--(business wire)---- $kalv--kalvista pharmaceuticals, inc. (nasdaq: kalv), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that the proposed name “sebetralstat” has been approved by the world health organization's international nonproprietary names (who-inn) expert committee and the american medical association's united states adopted names (ama-usan) cou
Latest News
2022-07-19 06:45:00 - Business Wire
KalVista Pharmaceuticals to Present at 1st Annual H.C. Wainwright Hereditary Angioedema Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be presenting at the 1st Annual H.C. Wainwright Hereditary Angioedema Conference (virtual) on Wednesday, July 20, 2022 at 12:00 p.m. ET. KalVista CEO Andrew Crockett will also participate as part of an expert panel discussing
2022-06-23 06:45:00 - Business Wire
KalVista Pharmaceuticals to Present Data at the 2022 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--EAACI 2022 accepts multiple abstracts from KalVista Pharmaceuticals, Inc.
2022-06-01 06:45:00 - Business Wire
KalVista Pharmaceuticals to Present at 13th Annual Jefferies Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be presenting at the 13th Annual Jefferies Global Healthcare Conference on Wednesday, June 8, 2022 at 11:30 a.m. ET. A live webcast of the presentation will be available on the Company's website at www.kalvista.com. An audio a
2022-02-02 07:30:00 - Business Wire
KalVista Pharmaceuticals to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that new data on KVD900, KalVista's lead drug program for oral on-demand treatment of hereditary angioedema (HAE) attacks, will be presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Scientific Meeting
2021-12-09 13:51:12 - Benzinga
KalVista Pharmaceuticals: Q2 Earnings Insights
KalVista Pharmaceuticals (NASDAQ:KALV) reported its Q2 earnings results on Thursday, December 9, 2021 at 06:30 AM. Here's what investors need to know about the announcement.
2021-11-09 07:00:00 - Business Wire
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the following investor conferences: Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021 at 9:20 a.m. EST Jefferies London Healthcare Conference on Tuesday, November 16, 2021 at 5:
2021-09-21 07:00:00 - Business Wire
KalVista Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, United Kingdom--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 8:40 a.m. ET. A live webcast of the presentation will be available on the Company's website at www.kalvista.co
2021-09-14 08:20:50 - Benzinga
FDA Lifts Clinical Hold On KalVista's Hereditary Angioedema Trial
The FDA has lifted the clinical hold on KalVista Pharmaceuticals Inc's (NASDAQ: KALV) Phase 2 trial of KVD824 for oral prophylactic treatment of hereditary angioedema (HAE). Related Content: KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824.
2021-09-14 06:30:00 - Business Wire
KalVista Pharmaceuticals Announces the Lifting of FDA Clinical Hold for Phase 2 Trial of KVD824
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company's Phase 2 clinical trial of KVD824 for oral prophylactic treatment of hereditary angioedema (HAE). “The execution of KOMPLETE, our Phase 2 clinical
2021-09-09 06:30:00 - Business Wire
KalVista Pharmaceuticals Reports First Fiscal Quarter Results
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2021. “We have made excellent progress in the rollout of our Phase 2 KOMPLETE clinical trial for KVD824,” said Andrew Crockett, Chief Executive